How Does Ambrisentan (Letairis) Work? Mechanism of Action Explained in Plain English

Ambrisentan (Letairis) is one of several medications used to treat pulmonary arterial hypertension (PAH), but it works through a specific biological pathway that makes it unique among available treatments. Understanding how it works can help you make sense of why it is prescribed, what to expect from treatment, and why your doctor chose it over other options.

First: What Is Happening in PAH?

To understand how ambrisentan works, you first need to understand what is going wrong in pulmonary arterial hypertension. In PAH, the small arteries that carry blood from the heart to the lungs become abnormally narrowed, stiff, and obstructed. This narrowing increases the resistance to blood flow through the lungs, forcing the right side of the heart to pump much harder.

Over time, this overworks the right ventricle. Without treatment, PAH leads to right heart failure and can be fatal. Three main biological pathways drive the narrowing:

The endothelin pathway: Endothelin-1 (ET-1) causes blood vessels to constrict and promotes abnormal cell growth in vessel walls

The nitric oxide pathway: Reduced nitric oxide production leads to vasoconstriction and impaired vasodilation

The prostacyclin pathway: Decreased prostacyclin production reduces the normal vasodilatory balance in the pulmonary vasculature

Ambrisentan targets the endothelin pathway specifically.

The Endothelin System: The Target of Ambrisentan

Endothelin-1 (ET-1) is a powerful peptide produced by the cells lining blood vessels. It is one of the most potent vasoconstrictors known — meaning it is extremely effective at causing blood vessels to tighten. In PAH, ET-1 levels are significantly elevated in the lungs, making it a major driver of the disease.

ET-1 exerts its effects by binding to two types of receptors: ETA and ETB. The functions are different:

ETA receptors: Found primarily on vascular smooth muscle cells. When activated, they cause vasoconstriction (vessel tightening) and promote abnormal cell proliferation in vessel walls.

ETB receptors: Found on endothelial cells (the inner lining). When activated, they promote vasodilation (vessel relaxation) and help clear ET-1 from circulation.

What Ambrisentan Does: Selectively Blocking ETA

Ambrisentan is a highly selective ETA receptor antagonist. With an affinity constant (Ki) of just 0.011 nM, it binds to the ETA receptor with extraordinary strength — more than 4,000 times more selectively for ETA than ETB. By blocking ETA, ambrisentan:

Prevents ET-1 from causing pulmonary vasoconstriction — blood vessels relax and widen

Reduces pulmonary vascular resistance — the heart does not have to work as hard

Inhibits ET-1-driven abnormal cell growth (proliferation) in pulmonary vessel walls

Preserves ETB function — allowing the beneficial vasodilatory and ET-1 clearance effects of ETB to continue

How Ambrisentan Differs from Other ERAs

There are three FDA-approved endothelin receptor antagonists for PAH:

Ambrisentan (Letairis): Highly selective for ETA (>4,000-fold selectivity over ETB). Once-daily dosing. No routine liver monitoring required.

Bosentan (Tracleer): Blocks both ETA and ETB receptors (non-selective). Twice-daily dosing. Requires monthly liver function monitoring.

Macitentan (Opsumit): Blocks both ETA and ETB with sustained receptor binding. Once daily. No routine liver monitoring required. Shown to reduce morbidity/mortality in SERAPHIN trial.

The ETA selectivity of ambrisentan may reduce some of the liver enzyme elevation that is more commonly seen with dual-blocking ERAs like bosentan, though the clinical importance of ETA versus dual selectivity continues to be studied.

The Clinical Evidence: What Does Ambrisentan Actually Do for Patients?

The two pivotal trials for ambrisentan — ARIES-1 and ARIES-2 — demonstrated that patients taking ambrisentan 5 mg or 10 mg walked 30 to 50 meters farther in a 6-minute walk test compared to placebo. Patients also had fewer PAH clinical worsening events.

The landmark AMBITION trial took this further by combining ambrisentan with tadalafil (a PDE5 inhibitor that works on the nitric oxide pathway). This combination — targeting two different biological pathways simultaneously — reduced the risk of clinical failure by 50% compared to either drug alone. This is why combination therapy is now standard of care for many PAH patients.

The Bottom Line

Ambrisentan works by blocking the ETA endothelin receptor, preventing the powerful vasoconstrictor endothelin-1 from tightening the blood vessels in the lungs. This reduces pulmonary arterial pressure, eases the workload of the right heart, and slows the progression of PAH. When combined with tadalafil, it addresses two distinct disease pathways simultaneously for even greater benefit. If you are having trouble finding ambrisentan at your pharmacy, medfinder can help. For a full patient guide to this medication, see what is ambrisentan and what is it used for.